Good manufacturing practice-grade cytotoxic T lymphocytes specific for latent membrane proteins (LMP)-1 and LMP2 for patients with Epstein-Barr virus-associated lymphoma

Cytotherapy

Volumn 13, Issue 5, 2011, Pages 518-522

  Bollard, Catherine M ^a,b   Gottschalk, Stephen ^a   Helen Huls, M ^a   Leen, Ann M ^a   Gee, Adrian P ^a   Rooney, Cliona M ^a  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b NONE   (United States)

Author keywords

standard operating procedures; T cell immunotherapy

Indexed keywords

LATENT MEMBRANE PROTEIN 1; LATENT MEMBRANE PROTEIN 2;

ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL EXPANSION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; EPSTEIN BARR VIRUS ASSOCIATED LYMPHOMA; GOOD MANUFACTURING PRACTICE; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LATENT PERIOD; LYMPHOBLASTOID CELL LINE; LYMPHOCYTE COUNT; LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY CONTROL;

EID: 79954475216     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.3109/14653249.2011.561983     Document Type: Article

References (13)

1. Bollard CM, Gottschalk S, Leen AM, Weiss H, Straathof KC, Carrum G, et al. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood. 2007;110:2838-45. (Pubitemid 350006936)
2. Bollard CM, Dotti G, Gottschalk S, Liu E, Sheehan A, Mims M, et al. Administration of tumor-specific cytotoxic T lymphocytes engineered to resist TGF-beta to patients with EBV-associated lymphomas. Blood. 2010;116:520.
3. Roskrow MA, Suzuki N, Gan Y-J, Sixbey JW, Ng CYC, Kimbrough S, et al. EBV-specific cytotoxic T lymphocytes for the treatment of patients with EBV positive relapsed Hodgkin's disease. Blood. 1998;91:2925-34. (Pubitemid 28227543)
4. Bollard CM, Aguilar L, Straathof KC, Gahn B, Huls MH, Rousseau A, et al. Cytotoxic T lymphocyte therapy for Epstein-Barr virus- Hodgkin's disease. J Exp Med. 2004; 200: 1623-33.
5. Gottschalk S, Edwards OL, Sili U, Huls MH, Goltsova T, Davis AR, et al. Generating CTL against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. Blood. 2003;101: 1905-12. (Pubitemid 36237592)
6. Shaffer DR, Rooney CM, Gottschalk S. Immunotherapeutic options for Epstein-Barr virus-associated lymphoproliferative disease following transplantation. Immunotherapy. 2010 Sep;2(5):663-71.
7. Leen AM, Ratnayake M, Foster AE, Heym K, Ahmed N, Rooney CM, et al. Contact activated monocytes: efficient antigen presenting cells for the stimulation of antigen-specific T cells. J Immunother. 2007 Jan;30(1):96-107. (Pubitemid 46052208)
8. Sili U, Huls MH, Davis AR, Gottschalk S, Brenner MK, Heslop HE, et al. Large-scale expansion of dendritic cellprimed polyclonal human cytotoxic T-lymphocytes using lymphoblastoid cell lines for adoptive immunotherapy. J Immunother. 2003;26:241-56. (Pubitemid 36686893)
9. Bollard CM, Straathof KC, Huls MH, Leen A, Lacuesta K, Davis A, et al. The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease. J Immunother. 2004; 27:317-27. (Pubitemid 38833328)
10. Vera JF, Brenner LJ, Gerdemann U, Ngo MC, Sili U, Liu H, et al. Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex). J Immunother. 2010;33: 305-15.
11. Miller G, Lipman M. Release of infectious Epstein-Barr virus by transformed marmoset leukocytes. Proc Natl Acad Sci USA. 1973;70:190-4.
12. Smith CA, Ng CYC, Heslop HE, Holladay MS, Richardson S, Turner EV, et al. Production of genetically modified EBV-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease. J Hematother. 1995;4:73-9.
13. Riddell SR, Greenberg PD. The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand antigen specific T cells. J Immunol Meth. 1990;128:189-201. (Pubitemid 20120262)